Mild-to-moderate liver impairment has no influence on the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor.

被引：0

作者：

Eriksson, UG ^{[1
]}

Eriksson-Lepkowska, M ^{[1
]}

Ohlsson, L ^{[1
]}

Wåhlander, K ^{[1
]}

机构：

[1] AstraZeneca R&D, Molndal, Sweden

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：P99 / P99

页数：1

共 50 条

[21] Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects
Eriksson, UG
Bredberg, U
Gislén, K
Johansson, LC
Frison, L
Ahnoff, M
Gustafsson, D
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (01) : 35 - 43
[22] Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects
Wolzt, M
Wollbratt, M
Svensson, M
Wåhlander, K
Grind, M
Eriksson, UG
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (07) : 537 - 543
[23] Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects
Michael Wolzt
Maria Wollbratt
Mia Svensson
Karin Wåhlander
Margaretha Grind
Ulf G. Eriksson
European Journal of Clinical Pharmacology, 2003, 59 : 537 - 543
[24] Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid
Gunnar Fager
Marie Cullberg
Maria Eriksson-Lepkowska
Lars Frison
Ulf G. Eriksson
European Journal of Clinical Pharmacology, 2003, 59 : 283 - 289
[25] Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid
Fager, G
Cullberg, M
Eriksson-Lepkowska, M
Frison, L
Eriksson, UG
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (04) : 283 - 289
[26] No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor to healthy male volunteers
Johansson, LC
Andersson, M
Fager, G
Gustafsson, D
Eriksson, UG
CLINICAL PHARMACOKINETICS, 2003, 42 (05) : 475 - 484
[27] No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers
Linda C. Johansson
Magnus Andersson
Gunnar Fager
David Gustafsson
Ulf G. Eriksson
Clinical Pharmacokinetics, 2003, 42 : 475 - 484
[28] A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays
Carlsson, SC
Mattsson, C
Eriksson, UG
Sarich, TC
Wåhlander, K
Eliasson, Å
Karlson, BW
Sheth, SB
Held, P
THROMBOSIS RESEARCH, 2005, 115 (1-2) : 9 - 18
[29] Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran
Schulman, S
Wåhlander, K
Lundström, T
Clason, SB
Eriksson, H
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (18): : 1713 - 1721
[30] Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran
Wernevik, LC
Nyström, P
Andersson, M
Johnsson, G
Bylock, A
Nakanishi, T
Eriksson, UG
CLINICAL PHARMACOKINETICS, 2006, 45 (01) : 85 - 94

← 1 2 3 4 5 →